文献速递胸部肿瘤

培美曲塞暴露预测晚期非小细胞肺癌毒性:一项前瞻性队列研究

Pemetrexed exposure predicts toxicity in advanced non-small-cell lung cancer: A prospective cohort study.
PubMed 文献 · Eur J Cancer · 2019-09-24

该前瞻性队列研究纳入165例接受一线或二线培美曲塞(/铂类)治疗的晚期非小细胞肺癌患者,通过群体药代动力学/药效学模型估算第一周期总暴露量(AUC1)。结果显示AUC1不预测初治患者的PFS/OS,但发生严重化疗相关不良事件的患者AUC1显著更高;模拟提示固定剂量或基于eGFR的给药可降低AUC个体间变异。

要点

  • AUC1不预测初治晚期NSCLC患者的PFS或OS。
  • 发生严重化疗相关不良事件者AUC1显著高于未发生者。
  • 固定剂量或基于eGFR给药可能降低AUC变异并预防毒性。

核心结论

  • 培美曲塞暴露量较高不增加PFS/OS,但与严重毒性发生显著相关。
  • 固定剂量可能降低药代动力学个体间变异,从而在保持疗效的同时预防毒性。

研究设计与样本

  • 前瞻性队列研究,纳入接受一线或二线培美曲塞(/铂类)治疗的晚期非小细胞肺癌患者。
  • 165例患者中106例可量化培美曲塞浓度(24hPK n=15;cyclePK n=106)。
  • 采用群体药代动力学/药效学模型估算第一周期总暴露量(AUC1),并与PFS/OS及严重化疗相关不良事件关联。
  • 模拟不同给药方案以最小化AUC的估计变异系数(CV)。

主要发现

  • 调整预后因素、性别、疾病分期和WHO体力状况评分后,AUC1不预测初治患者(n=95)的OS(HR=1.05,95%CI:1.00-1.11)和PFS(HR=1.03,95%CI:0.98-1.08)。
  • 发生严重化疗相关不良事件的患者(n=55)AUC1显著高于未发生者(n=51)(226±53 vs 190±31,p<0.001)。
  • 模拟显示基于eGFR给药(CV 18.5%)和固定剂量900 mg且eGFR<60 mL/min时减量25%(CV 19.1%)较体表面积给药(CV 22.5%)的AUC个体间变异更小。

关键数值与推荐

  • 初治患者OS的HR=1.05(95%CI:1.00-1.11),PFS的HR=1.03(95%CI:0.98-1.08)。
  • 严重化疗相关不良事件组AUC1为226±53,无事件组为190±31(p<0.001)。
  • 体表面积给药AUC的CV为22.5%,eGFR给药为18.5%,固定剂量900 mg(eGFR<60 mL/min减量25%)为19.1%。

临床怎么用

  • 临床可关注培美曲塞总暴露量与严重毒性的关联,高暴露患者可能需加强毒性监测。
  • 固定剂量或基于eGFR的给药策略可能减少药代动力学个体间变异,但需进一步验证后方可常规应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We explored whether total exposure to pemetrexed predicts effectiveness and toxicity in advanced non-small-cell lung cancer (NSCLC). Furthermore, we investigated alternative dosing schedules. METHODS: In this prospective cohort study, patients with advanced NSCLC receiving first- or second-line pemetrexed(/platinum) were enrolled. Plasma sampling was performed weekly (cyclePK) and within 24 h (24hPK) after pemetrexed administration. With population pharmacokinetic/pharmacodynamic modelling, total exposure to pemetrexed during cycle 1 (area under the curve during chemotherapy cycle 1 [AUC1]) was estimated and related to progression-free survival (PFS)/overall survival (OS). We compared mean AUC1 (mg·h/L) in patients with and without severe chemotherapy-related adverse events (AEs) during total treatment. Second, different dosing schedules were simulated to minimise the estimated variability (coefficient of variation [CV]) of AUC. RESULTS: For 106 of 165 patients, concentrations of pemetrexed were quantified (24hPK, n = 15; cyclePK, n = 106). After adjusting for prognostic factors, sex, disease stage and World Health Organisation performance score, AUC1 did not predict PFS/OS in treatment-naive patients (n = 95) (OS, hazard ratio [HR] = 1.05, 95% confidence interval [CI]: 1.00-1.11; PFS, HR = 1.03, 95% CI: 0.98-1.08). Patients with severe chemotherapy-related AEs (n = 55) had significantly higher AUC1 values than patients without them (n = 51) (226 ± 53 vs 190 ± 31, p < 0.001). Compared with body surface area-based dosing (CV: 22.5%), simulation of estimated glomerular filtration rate (eGFR)-based dosing (CV 18.5%) and fixed dose of 900 mg with 25% dose reduction, if the eGFR<60 mL/min (CV: 19.1%), resulted in less interindividual variability of AUC. CONCLUSIONS: Higher exposure to pemetrexed does not increase PFS/OS but is significantly associated with increased occurrence of severe toxicity. Our findings suggest that fixed dosing reduces interpatient pharmacokinetic variability and thereby might prevent toxicity, while preserving effectiveness.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Visser S, Koolen SLW, de Bruijn P, et al. Pemetrexed exposure predicts toxicity in advanced non-small-cell lung cancer: A prospective cohort study. Eur J Cancer. 2019. PMID: 31561135. doi:10.1016/j.ejca.2019.08.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。